Mayer Brown represents Nestlé in $2.6 billion acquisition of Aimmune Therapeutics

Mayer Brown is advising Nestlé Health Science (NHSc) on the $2.6 billion acquisition of Aimmune Therapeutics, Inc. (Aimmune), a biopharmaceutical company that is developing and commercializing treatments for potentially life-threatening food allergies. The transaction is expected to close in the fourth quarter of 2020 and is subject to the satisfaction or waiver of customary closing conditions.

Aimmune’s Palforzia is the first and only FDA-approved treatment to help reduce the severity of allergic reaction to peanuts, including anaphylaxis, in children aged 4 through 17. The acquisition is an extension of NHSc’s food allergy portfolio, creating a broader spectrum of solutions for children living with food allergies.

The team is led by Corporate & Securities partners David Carpenter (NY), Andrew Noreuil and Bruce Perce and associates Ryan Ferris (all Chicago), Jeremy Zucker, Ann Kang and Adam Lerner (all NY) and includes: Corporate & Securities – partner David Bakst (NY) and associates Stephanie Hurst (LA) and Jengeih Tamba (DC); IP – partners Rich Assmus, Erick J. Palmer (both Chicago), Joseph Mahoney (Charlotte) and Michelle Gross (NorCal) and associates Lana Khoury and Ryan Babcock (both NY); Employment & Benefits – partners Debra Hoffman (Chicago), Christopher Fisher (London) and Guido Zeppenfeld and associates Hasine Azim, Marius Höfler (all Frankfurt), George Aldous (London) and Hillary August (NY); Litigation & Dispute Resolution – partners Dan Ring (Chicago), Elizabeth Mann (LA) and Audrey Harris, counsel Meytal McCoy (both DC) and Jaimy Hamburg (Chicago) and associate Juliet Gunev (NY); Tax Transactions & Consulting – partners Remmelt Reigersman (NorCal) and Jim Barry (Chicago) and associate Brennan Young (NY); and Real Estate Markets – partner David Saye and staff attorney Ryan Lifland (both Charlotte).